Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CALML3 | P27482 | 5/20 | 0.43 |
| ▸ | MAOA | P21397 | 13/20 | 0.43 |
| ▸ | F10 | P00742 | 1/20 | 0.41 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.39 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.39 |
| ▸ | MAOB | P27338 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7210278 | 0.93 | MAOA (0.44) | CALML3MAOACYP2C19MAOB | |
| SCHEMBL7084805 | 0.91 | F10 (0.39) | CALML3MAOAF10CYP2C9CYP2C19 | |
| SCHEMBL7081004 | 0.90 | CALML3 (0.42) | CALML3MAOACYP2C9CYP2C19 | |
| SCHEMBL7081443 | 0.90 | MAOA (0.40) | CALML3MAOACYP2C9CYP2C19 | |
| SCHEMBL7081440 | 0.90 | MAOA (0.40) | CALML3MAOACYP2C9CYP2C19 | |
| SCHEMBL7077029 | 0.90 | CALML3 (0.41) | CALML3MAOACYP2C9CYP2C19 | |
| SCHEMBL7081104 | 0.90 | CALML3 (0.41) | CALML3MAOACYP2C9CYP2C19MAOB | |
| SCHEMBL7081106 | 0.90 | CALML3 (0.41) | CALML3MAOACYP2C9CYP2C19MAOB | |
| SCHEMBL7081938 | 0.90 | CALML3 (0.41) | CALML3MAOACYP2C9CYP2C19 | |
| SCHEMBL7079278 | 0.89 | MAOA (0.41) | CALML3MAOACYP2C9CYP2C19 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2007138381-A2 | PHOSPHONATED OXAZOLIDINONES AND USES THEREOF FOR THE PREVENTION AND TREATMENT OF BONE AND JOINT INFECTIONS | TARGANTA THERAPEUTICS INC. (CA) | 2007-12-06 | — | — | WO | disclosed |
| US-6617339-B1 | 5-Isoxazolyloxymethyl-3-((dihydroxypropanoyl)-4-tetrahydropyri dyl-3,5- difluorophenyl)oxazolidinone, or the phosphated derivative or its disodium salt; antibiotic with useful activity against Grampositive pathogens | SYNGENTA LIMITED (GB) | 2003-09-09 | — | — | US | disclosed |
| US-20030144263-A1 | Oxazolidinone derivatives, process for their preparation and pharmaceutical compositions containing them | SYNGENTA LIMITED (GB) | 2003-07-31 | — | — | US | disclosed |
| EP-1082323-A2 | OXAZOLIDINONE DERIVATIVES, PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | AstraZeneca UK Limited (GB) | 2001-03-14 | — | — | EP | disclosed |
| WO-1999064417-A2 | OXAZOLIDINONE DERIVATIVES, PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | ASTRAZENECA AB (SE) | 1999-12-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030144263-A1 | Oxazolidinone derivatives, process for their preparation and pharmaceutical compositions containing them | CYP3A5, CYP2D6, OXA1L | CALML3 4622/4885MAOA 1654/4885F10 547/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.